TY - JOUR
T1 - A bibliometric analysis and systematic review of drug repurposing against drug-resistant ESKAPE pathogens
T2 - a particular focus on Pseudomonas aeruginosa
AU - Guo, Sitong
AU - Li, Lin
AU - Zhang, Qianqian
AU - Liu, Huanxiang
AU - Yao, Xiaojun
AU - Liang, Liang
AU - Chen, Chunxia
N1 - Publisher Copyright:
Copyright © 2025 Guo, Li, Zhang, Liu, Yao, Liang and Chen.
PY - 2025
Y1 - 2025
N2 - Purpose: Drug-resistant ESKAPE pathogens represent a major global health challenge. This study included a comprehensive bibliometric analysis and systematic review to evaluate drug repurposing efforts against these pathogens, with a particular focus on Pseudomonas aeruginosa. Methods: We searched the Web of Science Core Collection (2001–April 2025) using the query “ESKAPE AND Drug Resistance AND Drug Repositioning” and performed bibliometric analysis with Bibliometrix (RStudio 4.3.2), VOSviewer 1.6.20, and CiteSpace 6.2R6. In parallel, a systematic review was conducted across PubMed, Embase, Web of Science, and Cochrane Library to identify non-antibiotic agents with reported activity against resistant ESKAPE pathogens. Results: A total of 443 articles were analyzed bibliometrically, and 141 eligible studies were included in the systematic review, among which 31 focused on drug-resistant P. aeruginosa. The United States, China, and India were the leading contributors, with notable institutional collaborations. Repurposed agents such as niclosamide and mitomycin C exhibited antibacterial activity through mechanisms including membrane permeability disruption, quorum sensing inhibition, and biofilm suppression. Many agents also showed synergistic effects when combined with conventional antibiotics. Conclusion: By integrating bibliometric mapping with systematic evidence synthesis, this study uniquely highlights both research trends and therapeutic potential in drug repurposing for ESKAPE pathogens. While repurposing offers advantages of reduced cost and faster development, translation remains constrained by toxicity, pharmacokinetics, and regulatory hurdles. Limitations include restriction to English-language studies and the use of selected databases. Future efforts should emphasize in vivo validation, clinical trials, and innovative delivery systems to accelerate clinical application. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251053437.
AB - Purpose: Drug-resistant ESKAPE pathogens represent a major global health challenge. This study included a comprehensive bibliometric analysis and systematic review to evaluate drug repurposing efforts against these pathogens, with a particular focus on Pseudomonas aeruginosa. Methods: We searched the Web of Science Core Collection (2001–April 2025) using the query “ESKAPE AND Drug Resistance AND Drug Repositioning” and performed bibliometric analysis with Bibliometrix (RStudio 4.3.2), VOSviewer 1.6.20, and CiteSpace 6.2R6. In parallel, a systematic review was conducted across PubMed, Embase, Web of Science, and Cochrane Library to identify non-antibiotic agents with reported activity against resistant ESKAPE pathogens. Results: A total of 443 articles were analyzed bibliometrically, and 141 eligible studies were included in the systematic review, among which 31 focused on drug-resistant P. aeruginosa. The United States, China, and India were the leading contributors, with notable institutional collaborations. Repurposed agents such as niclosamide and mitomycin C exhibited antibacterial activity through mechanisms including membrane permeability disruption, quorum sensing inhibition, and biofilm suppression. Many agents also showed synergistic effects when combined with conventional antibiotics. Conclusion: By integrating bibliometric mapping with systematic evidence synthesis, this study uniquely highlights both research trends and therapeutic potential in drug repurposing for ESKAPE pathogens. While repurposing offers advantages of reduced cost and faster development, translation remains constrained by toxicity, pharmacokinetics, and regulatory hurdles. Limitations include restriction to English-language studies and the use of selected databases. Future efforts should emphasize in vivo validation, clinical trials, and innovative delivery systems to accelerate clinical application. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251053437.
KW - bibliometric analysis
KW - drug repurposing
KW - drug-resistant ESKAPE
KW - drug-resistant Pseudomonas aeruginosa
KW - systematic review
UR - https://www.scopus.com/pages/publications/105020597259
U2 - 10.3389/fmicb.2025.1669585
DO - 10.3389/fmicb.2025.1669585
M3 - Review article
AN - SCOPUS:105020597259
SN - 1664-302X
VL - 16
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
M1 - 1669585
ER -